Search
Categories


Posts Tagged ‘anxiety’

Despite Known Health Risks Long-Term Use Of Anti-Anxiety Drugs Continues In B.C.

Sunday, June 6th, 2010

Drugs to treat anxiety and sleep disorders are still being prescribed for extended periods to British Columbian patients – and i ncreasingly so for baby boomers – despite warnings against long-term use, according to a University of British Columbia study. Published online in the journal Health Policy, the study by researchers at UBC’s Centre for Health Services and Policy Research (CHSPR) is the first of its kind to examine the use of benzodiazepines (more…)

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder

Monday, May 31st, 2010

Generalized anxiety disorder (GAD) is a prevalent and impairing disorder, associated with extensive psychiatric and medical comorbidity and usually characterized by a chronic course. Different drugs have been investigated in GAD; among them are the following: 1) SSRIS: paroxetine, sertraline, fluvoxamine and escitalopram; 2) SNRI1S: venlafaxine; 3) benzodiaze pines (BZS): alprazolam, diazepam and lorazepam; 4) azapirones (AZAS): buspirone; 5) (more…)

Anxiety Medications

Sunday, May 30th, 2010

Antianxiety medications help to calm and relax the anxious person and remove the troubling symptoms. There are a number of antianxiety medications currently available. The preferred medications for most anxiety disorders are the benzodiazepines such as Valium, Xanax/Zanex, and Ativan. (Source: About.com Mental Health)

Erratum to: Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine

Saturday, May 29th, 2010

Content Type Journal ArticleCategory ErratumDOI 10.1007/s00213-010-1837-4Authors
J. M. P. Baas, Utrecht University Department of Experimental Psychology, Faculty of Social Sciences Van Unnik Building, Heidelberglaan 2 3584 CS Ut recht The NetherlandsN. Mol, Utrecht University Department of Experimental Psychology, Faculty of Social Sciences Van Unnik Building, Heidelberglaan 2 3584 CS Utrecht The NetherlandsJ. L. Kenemans, Utrecht University (more…)

Despite Known Health Risks Long-Term Use Of Anti-Anxiety Drugs Continues In B.C.

Friday, May 28th, 2010

Drugs to treat anxiety and sleep disorders are still being prescribed for extended periods to British Columbian patients – and increasingly so for baby boomers – despite warnings against long-term use, according to a University of British Columbi a study. Published online in the journal Health Policy, the study by researchers at UBC’s Centre for Health Services and Policy Research (CHSPR) is the first of its kind to examine the use of benzodiazepines (more…)

Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model

Wednesday, May 26th, 2010

To evaluate acute onset of anxiolytic activity using a dental anxiety model, 89 patients were randomised to double-blind single dose pregabalin 150 mg, alprazolam 0.5 mg or placebo 4 h before a scheduled dental procedure. A Dental Anxiety Total score >12 (moderate-to-severe) without meeting Diagnostic and Statistical Manual of Mental Di sorders (Fourth edition) (DSM-IV) anxiety disorder criteria was required. Efficacy and safety, assessed (more…)

Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine

Saturday, May 22nd, 2010

Conclusion  Even though fear-potentiated startle may be used to translate preclini cal evidence to human populations, methodological issues
still hamper the application of this model to early screening of putative anxiolytic drugs.

Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-009-1516-5Authors
J. M. P. Baas, Utrecht University Department of Experimental Psychology, Faculty of Social Sciences (more…)

A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO2 models of experimental human anxiety

Friday, May 21st, 2010

In conclusion, our results show that zolpidem shows some anxiolytic efficacy in the 7.5% CO2 model, similar to alprazolam, and this is the first report of such an effect of zolpidem in a model of a nxiety. These and other studies of benzodiazepines in clinical and volunteer studies suggest a definite role of the GABA-A receptor in CO2-induced anxiety, and it would be of interest to examine other GABA-A receptor subtype selective drugs, which (more…)

Review: Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials

Friday, May 21st, 2010

The objective of this study was to assess the effectiveness and efficacy of benzodiazepines in the treatment of GAD based on trial drop-out rates. We used a systematic review of randomized controlled trials that compared any of the thr ee best established benzodiazepines (diazepam, Lorazepam and aLprazolam) against placebo. Our primary outcome for effectiveness was withdrawal for any reason. Our secondary (more…)

Treatments for Anxiety

Thursday, May 20th, 2010

Anxiety is a well-understood and readily treated condition. There are many different kinds of specific anxiety disorders, ranging from generalized anxiety disorder (GAD) to panic attacks. The below treatment options cover general anxiety disorders and are usually recomme nded in some combination.
Medications
The medications most often used to treat anxiety are a class of drugs known as benzodiazepines (also called “minor tranquilizers”). (more…)

Page 1 of 3123